Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01, RTT News reports. During the same period last year, the business earned ($0.37) EPS.
Nuvectis Pharma Stock Performance
Shares of NVCT stock traded up $0.35 during mid-day trading on Thursday, hitting $8.50. The company’s stock had a trading volume of 50,776 shares, compared to its average volume of 102,621. Nuvectis Pharma has a 52 week low of $5.85 and a 52 week high of $12.10. The company’s fifty day simple moving average is $6.81 and its 200-day simple moving average is $6.68. The company has a market cap of $158.53 million, a PE ratio of -6.32 and a beta of 0.41.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Nuvectis Pharma in a report on Tuesday, August 6th.
About Nuvectis Pharma
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Recommended Stories
- Five stocks we like better than Nuvectis Pharma
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Consumer Discretionary Stocks Explained
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Atlassian Is Up +60% in Three Months—What’s Causing the Rally?
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
